However, the fact that FOXO3 is often inactivated in cancer cells and even more so in the drug resistant cells, suggesting that the ability of FOXO3 to induce PERK in response to GCN2 inactivation is compromised in the cancer cells, and even more in the drug resistant cells. This evidence concerns the gene EIF2AK4 and cancer.